IVC Wealth Advisors LLC Has $237,000 Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

IVC Wealth Advisors LLC trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 20.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 600 shares of the medical instruments supplier’s stock after selling 150 shares during the quarter. IVC Wealth Advisors LLC’s holdings in West Pharmaceutical Services were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock worth $3,170,007,000 after buying an additional 104,740 shares during the last quarter. Franklin Resources Inc. increased its position in West Pharmaceutical Services by 1.3% during the fourth quarter. Franklin Resources Inc. now owns 2,105,589 shares of the medical instruments supplier’s stock worth $741,420,000 after acquiring an additional 28,010 shares during the period. Artisan Partners Limited Partnership increased its position in West Pharmaceutical Services by 23.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock worth $690,530,000 after acquiring an additional 369,792 shares during the period. Brown Advisory Inc. increased its position in West Pharmaceutical Services by 8.4% during the fourth quarter. Brown Advisory Inc. now owns 1,414,431 shares of the medical instruments supplier’s stock worth $498,049,000 after acquiring an additional 109,369 shares during the period. Finally, Norges Bank bought a new position in West Pharmaceutical Services during the fourth quarter worth $300,250,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the sale, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Performance

WST stock traded down $1.20 on Wednesday, reaching $321.40. 227,206 shares of the company were exchanged, compared to its average volume of 535,777. West Pharmaceutical Services, Inc. has a 12 month low of $310.00 and a 12 month high of $415.73. The stock’s fifty day moving average price is $339.14 and its 200 day moving average price is $359.83. The firm has a market capitalization of $23.41 billion, a PE ratio of 42.40, a PEG ratio of 5.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. The business had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. West Pharmaceutical Services’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.98 earnings per share. On average, research analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.25%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.55%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.